Procyon Advisors LLC Has $1.44 Million Stake in Pfizer Inc. (NYSE:PFE)



Procyon Advisors LLC increased its position in Pfizer Inc. (NYSE:PFE – Get Rating) by 1.2% during the first quarter, HoldingsChannel reports. The institutional investor owned 27,718 shares of the biopharmaceutical shares the company’s stock after acquiring an additional 325 during the period. Procyon Advisors LLC’s holdings in Pfizer were worth $1,435,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Norges Bank bought a new position in shares of Pfizer in the fourth quarter valued at approximately $3,351,891,000. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main lifted its holdings in shares of Pfizer by 577.8% during the 4th quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 12,247,903 shares of the biopharmaceutical company’s stock worth $715,270,000 after acquiring an additional 10,440,786 shares during the period. Coatue Management LLC acquired a new stake in shares of Pfizer during the 4th quarter valued at about $608,919,000. Darwin Global Management Ltd. bought a new stake in Pfizer in the fourth quarter valued at about $454,553,000. Finally, State Street Corp raised its position in Pfizer by 1.8% in the fourth quarter. State Street Corp now owns 284,816,832 shares of the biopharmaceutical company’s stock worth $16,818,434,000 after purchasing an additional 5,013,651 shares in the last quarter. Hedge funds and other institutional investors own 66.50% of the company’s stock.

In related news, SVP Jennifer B. Damico sold 4,218 shares of the business’s stock in a transaction on Tuesday, June 7th. The shares were sold at an average price of $53.96, for a total value of $227,603.28. Following the sale, the senior vice president now directly owns 10,846 shares of the company’s stock, valued at approximately $585,250.16. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Jennifer B. Damico sold 4,000 shares of the stock in a transaction dated Monday, May 16th. The stock was sold at an average price of $50.50, for a total value of $202,000.00. Following the transaction, the senior vice president now owns 15,064 shares of the company’s stock, valued at approximately $760,732. The disclosure for this sale can be found here. Insiders have sold a total of 41,126 shares of company stock worth $2,075,003 in the last quarter. 0.05% of the stock is currently owned by company insiders.

PFE has been the topic of a number of analyst reports. SVB Leerink began coverage on Pfizer in a research report on Monday, May 23rd. They issued a “market perform” rating and a $55.00 price target on the stock. Wells Fargo & Company cut their price target on shares of Pfizer from $60.00 to $55.00 in a report on Wednesday, May 4th. Barclays set a $52.00 price objective on shares of Pfizer in a research note on Monday. StockNews.com raised Pfizer from a “buy” rating to a “strong-buy” rating in a report on Tuesday, April 19th. Finally, The Goldman Sachs Group set a $51.00 price objective on Pfizer in a research note on Wednesday, May 25th. Nine equities research analysts have rated the stock with a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, Pfizer currently has a consensus rating of “Moderate Buy” and a consensus target price of $57.26.

Shares of NYSE PFE opened at $50.94 on Thursday. Pfizer Inc. has a 52-week low of $38.82 and a 52-week high of $61.71. The company has a debt-to-equity ratio of 0.43, a quick ratio of 1.13 and a current ratio of 1.39. The stock has a market cap of $285.82 billion, a P/E ratio of 11.68, a P/E/G ratio of 0.63 and a beta of 0.76. The firm has a 50 day moving average price of $50.51 and a 200 day moving average price of $52.19.

Pfizer (NYSE:PFE – Get Rating) last announced its quarterly earnings results on Tuesday, May 3rd. The biopharmaceutical company reported $1.62 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.66 by ($0.04). The firm had revenue of $25.66 billion during the quarter, compared to analyst estimates of $24.73 billion. Pfizer had a net margin of 26.97% and a return on equity of 38.29%. Pfizer’s quarterly revenue was up 76.8% on a year-over-year basis. During the same period last year, the firm earned $0.93 EPS. Analysts predict that Pfizer Inc. will post 6.61 earnings per share for the current fiscal year.

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 6th. Stockholders of record on Wednesday, June 29th will be given a dividend of $0.40 per share. This represents a $1.60 dividend on an annual basis and a dividend yield of 3.14%. The ex-dividend date of this dividend is Thursday, July 28th. Pfizer’s dividend payout ratio is currently 36.70%.

Pfizer Company Profile (Get Rating)

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women’s health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands.

Recommended Stories

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE – Get Rating).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)



Receive News & Ratings for Pfizer Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Pfizer and related companies with MarketBeat.com’s FREE daily email newsletter.

.

Leave a Comment